180 related articles for article (PubMed ID: 2752648)
1. [Effect of LDL-apheresis on a case of Cerebrotendinous Xanthomatosis].
Fukuo Y; Hayama N; Hara K; Terashi A; Seta K
Rinsho Shinkeigaku; 1989 Feb; 29(2):196-201. PubMed ID: 2752648
[TBL] [Abstract][Full Text] [Related]
2. Normalisation of serum cholestanol concentration in a patient with cerebrotendinous xanthomatosis by combined treatment with chenodeoxycholic acid, simvastatin and LDL apheresis.
Dotti MT; Lütjohann D; von Bergmann K; Federico A
Neurol Sci; 2004 Oct; 25(4):185-91. PubMed ID: 15549503
[TBL] [Abstract][Full Text] [Related]
3. Treatment of cerebrotendinous xanthomatosis with low-density lipoprotein (LDL)-apheresis.
Mimura Y; Kuriyama M; Tokimura Y; Fujiyama J; Osame M; Takesako K; Tanaka N
J Neurol Sci; 1993 Feb; 114(2):227-30. PubMed ID: 8445406
[TBL] [Abstract][Full Text] [Related]
4. [Cerebrotendinous xanthomatosis].
Berginer VM
Zh Nevropatol Psikhiatr Im S S Korsakova; 1992; 92(4):13-22. PubMed ID: 1333699
[TBL] [Abstract][Full Text] [Related]
5. A novel pathway for biosynthesis of cholestanol with 7 alpha-hydroxylated C27-steroids as intermediates, and its importance for the accumulation of cholestanol in cerebrotendinous xanthomatosis.
Skrede S; Björkhem I; Buchmann MS; Hopen G; Fausa O
J Clin Invest; 1985 Feb; 75(2):448-55. PubMed ID: 3919058
[TBL] [Abstract][Full Text] [Related]
6. A case of cerebrotendinous xanthomatosis: effects of ursodeoxycholic acid administration on serum bile acids and cholestanol.
Kimura S; Beppu T; Kugai N; Koide Y; Fujita T; Iida K; Yamashita N; Yamashita K; Seyama Y
Jpn J Med; 1982 Jul; 21(3):210-5. PubMed ID: 7143816
[TBL] [Abstract][Full Text] [Related]
7. [Cerebrotendinous xanthomatosis--a case of brain MRI abnormality and osteoporosis].
Kubota R; Nakagawa M; Nakamura A; Kuriyama M; Osame M
Rinsho Shinkeigaku; 1992 May; 32(5):488-93. PubMed ID: 1333927
[TBL] [Abstract][Full Text] [Related]
8. Increased concentrations of cholestanol and apolipoprotein B in the cerebrospinal fluid of patients with cerebrotendinous xanthomatosis. Effect of chenodeoxycholic acid.
Salen G; Berginer V; Shore V; Horak I; Horak E; Tint GS; Shefer S
N Engl J Med; 1987 May; 316(20):1233-8. PubMed ID: 3106810
[TBL] [Abstract][Full Text] [Related]
9. Cerebrotendinous xanthomatosis: a defect in cellular sterol biosynthetic control.
Barron JL; Maxwell JU; Rutherfoord GS
J Inherit Metab Dis; 1982; 5(2):91-3. PubMed ID: 6820431
[TBL] [Abstract][Full Text] [Related]
10. A novel route for the biosynthesis of cholestanol, and its significance for the pathogenesis of cerebrotendinous xanthomatosis.
Skrede S; Bjørkhem I
Scand J Clin Lab Invest Suppl; 1985; 177():15-21. PubMed ID: 3865344
[TBL] [Abstract][Full Text] [Related]
11. Combined treatment with chenodeoxycholic acid and pravastatin improves plasma cholestanol levels associated with marked regression of tendon xanthomas in cerebrotendinous xanthomatosis.
Nakamura T; Matsuzawa Y; Takemura K; Kubo M; Miki H; Tarui S
Metabolism; 1991 Jul; 40(7):741-6. PubMed ID: 1908036
[TBL] [Abstract][Full Text] [Related]
12. [Hypothyroidism with increased serum levels of cholestanol and bile alcohol--analogous symptoms to cerebrotendinous xanthomatosis].
Idouji K; Kuriyama M; Fujiyama J; Osame M; Hoshita T
Rinsho Shinkeigaku; 1991 Apr; 31(4):402-6. PubMed ID: 1914325
[TBL] [Abstract][Full Text] [Related]
13. [A case of familial type IIa hypercholesterolemia with the clinical features similar to cerebrotendinous xanthomatosis].
Sakae N; Taniwaki T; Arakawa K; Yamada T; Kira J
Rinsho Shinkeigaku; 2000 Mar; 40(3):222-6. PubMed ID: 10885331
[TBL] [Abstract][Full Text] [Related]
14. [Magnetic resonance of the brain and Achilles tendon in cerebrotendinous xanthomatosis].
Pardo J; Prieto JM; Rodríguez JR; Vadillo J; Dapena MD; Noya M
Neurologia; 1993 Oct; 8(8):268-70. PubMed ID: 8240840
[TBL] [Abstract][Full Text] [Related]
15. [Cerebrotendinous xanthomatosis: report of 4 patients].
Ferrándiz-Pulido C; Bartralot R; Girós M; Bassas P; Heras C; Bodet D; Savall R; García-Patos V
Actas Dermosifiliogr; 2009 Apr; 100(3):222-6. PubMed ID: 19457308
[TBL] [Abstract][Full Text] [Related]
16. [Cerebrotendinous xanthomatosis: utility of nuclear magnetic resonance image in the follow-up and response to treatment].
Cuende E; Gómez-Rz de Mendarozqueta M; Vesga JC; Saracíbar N; Ibáñez-Avilés A; Castellano-Hurtado C
Rev Neurol; 1996 Dec; 24(136):1535-8. PubMed ID: 9064170
[TBL] [Abstract][Full Text] [Related]
17. Transformation of 4-cholesten-3-one and 7 alpha-hydroxy-4-cholesten-3-one into cholestanol and bile acids in cerebrotendinous xanthomatosis.
Salen G; Shefer S; Tint GS
Gastroenterology; 1984 Aug; 87(2):276-83. PubMed ID: 6735073
[TBL] [Abstract][Full Text] [Related]
18. Combined treatment with LDL-apheresis, chenodeoxycholic acid and HMG-CoA reductase inhibitor for cerebrotendinous xanthomatosis.
Ito S; Kuwabara S; Sakakibara R; Oki T; Arai H; Oda S; Hattori T
J Neurol Sci; 2003 Dec; 216(1):179-82. PubMed ID: 14607320
[TBL] [Abstract][Full Text] [Related]
19. [Cerebrotendinous xanthomatosis: long-term treatment with chenodesoxycholic acid (author's transl)].
Wolf LM; Houdent C; Laudat MH; Brasseur G; Balacheff O; Uzac L
Nouv Presse Med; 1982 Mar; 11(11):855-7. PubMed ID: 7070978
[TBL] [Abstract][Full Text] [Related]
20. [Cerebrotendinous xanthomatosis].
Verrips A
Ned Tijdschr Geneeskd; 2001 Sep; 145(35):1673-7. PubMed ID: 11561482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
